Quattro Financial Advisors LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quattro Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2,517.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,000 shares of the biopharmaceutical company’s stock after buying an additional 4,809 shares during the quarter. Quattro Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $747,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $390,438,000. Capital International Investors boosted its position in Alnylam Pharmaceuticals by 15.8% during the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares in the last quarter. Wellington Management Group LLP boosted its position in Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares in the last quarter. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after purchasing an additional 287,064 shares in the last quarter. Finally, abrdn plc boosted its position in Alnylam Pharmaceuticals by 910.7% during the fourth quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after purchasing an additional 209,691 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 1.8 %

Shares of Alnylam Pharmaceuticals stock traded up $4.29 on Tuesday, reaching $247.61. 1,579,308 shares of the company were exchanged, compared to its average volume of 888,290. The company’s 50-day moving average is $161.82 and its two-hundred day moving average is $164.96. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.40) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.92 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 2,103 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $485,771.97. Following the sale, the chief marketing officer now directly owns 15,609 shares of the company’s stock, valued at $3,605,522.91. The disclosure for this sale can be found here. In the last ninety days, insiders sold 67,357 shares of company stock valued at $13,436,711. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 25th. Barclays upped their target price on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a research note on Tuesday, June 25th. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Bank of America upped their target price on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $246.41.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.